MedTrace Logo

Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN

NCT05850845 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-05-09

No results posted yet for this study

Summary

Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined cyclophosphamide regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.

Conditions

  • Hyperspectral Imaging
  • Idiopathic Membranous Nephropathy
  • Cyclophosphamide

Interventions

DEVICE

Microscopic hyperspectral imaging system

CTX for idiopathic membranous nephropathy

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-25
Primary Completion
2023-07-20
Completion
2023-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05850845 on ClinicalTrials.gov